TAIPEI, 13 de noviembre de 2025 /PRNewswire/ -- EirGenix Inc. (TWSE: 6589) anunció el 12 de noviembre la firma de un segundo acuerdo global de licencia exclusiva con Sandoz AG (SIX:SDZ/OTCQX:SDZNY), líder internacional en biosimilares, para la comercialización de su biosimilar para el...
Hence then, the article about eirgenix ha firmado el acuerdo de licencia comercial para su segundo biosimilar de her2 eg1206a was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( EirGenix ha firmado el acuerdo de licencia comercial para su segundo biosimilar de HER2, EG1206A )
Also on site :
- Russian oil supplies to India surge – media
- Prime Video Touts India as ‘Most Important’ Global Market
- Meet Mark Zuckerberg’s college roommate. He’s an Olympian-turned-VC exec who now invests in your favorite celebrity businesses